Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer (NSCLC)

ABSTRACT Background Oncogenic driver mutations are responsible for both the initiation and maintenance of cancers including NSCLC. Elucidation of driver mutation occurrence in NSCLC and its relationship with clinical outcome are imperative to personalized treatment of NSCLC. Methods Tumor tissues from a total of 488 Chinese NSCLC patients at various stages were enrolled in this retrospective study. Mutations were assessed using amplification-refractory mutation system (ADx-ARMSTM)-PCR and verified using direct sequencing. ERCC1 levels were measured using immunohistochemistry method. The relationship between tumor gene mutation status and patient's disease-free survival (DFS) was analyzed. Results Of the 488 NSCLC tumors, 28 had EML4-ALK fusions (5.7%). Female (10.38%), young age ( Conclusion Oncogenic driver mutations define molecular subsets of Chinese NSCLC patients with distinct clinicopathological characteristics. EML4-ALK fusion might be a significant prognostic biomarker for locally advanced stage NSCLC. Disclosure All authors have declared no conflicts of interest.